New MaNufacturiNg facility During 2012, Ceapro selected a suitable location and commenced the work for its new home in  south Edmonton. The new and unique facility comprising about 20,000 sq. ft. will incorporate  all Ceapro operations including its head office, research and development, and manufactur- ing. It will be a facility that will allow new potential products developed in our laboratory to  be scaled up in the Pilot scale wing, prior to full commercial production. This has been a long  process and has resulted from a significant corporate effort over the last two years. Prior to  selecting the location, we undertook a thorough due diligence of alternative manufacturing  options as well as alternative locations and the answers came back very clearly: Ceapro needs  to do its own manufacturing and the location selected was the most preferable. Since we moved in to our Leduc facility in 2007, several factors besides revenue growth have  contributed to the need to move. We anticipate that quality standards and regulation will con- tinue to increase in all the sectors we will serve. Accordingly, this facility has been planned to  meet cGMP international standards. In addition, Ceapro will seek a Natural Health Products site  license from Health Canada.  Ceapro has a rich portfolio of technologies to support its platform products and many of these  opportunities can only be developed in a new facility due to both space and regulatory restric- tions. The convergence of the personal care markets Ceapro currently serves as well as the food  and nutrition and pharmaceutical markets provide a huge opportunity to provide solutions for  the insatiable appetite for more natural health solutions.  Our product platforms will finally have the opportunity to exploit new market opportunities as  a result of technology advancements and this new facility. While we may sell oat beta glucan  today in a liquid form for anti-aging products in personal care, we may be using our oat beta  glucan powders under development for functional drinks to reduce the risk of high cholesterol  and metabolic disease or for incorporating into wound healing products in the future.  Our other products also have potential to enter new large markets. The combination of Ceapro’s  strong technology, market sector convergence, health care market needs, and our new facility  will allow for the potential of explosive growth in the coming years for Ceapro. A special thank you must be given to the Government of Alberta. They have recognized the  huge potential of bio-industrial processing today and created an environment conducive to  growing this sector. We will work very hard to become a Bio-Industrial Centre of Excellence  that we can all be proud of. 4